Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
117 Leser
Artikel bewerten:
(0)

Active-Investors: Blog Exposure - XBiotech To Present Data From Phase-2 Study On MABp1 For Treatment Of Hidradenitis Suppurativa at EHSF Conference

LONDON, UK / ACCESSWIRE / January 29, 2018 / Active-Investors.com has just released a free research report on XBiotech Inc. (NASDAQ: XBIT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=XBIT as the Company's latest news hit the wire. On January 26, 2018, the Company announced additional results of its Phase-2 study evaluating its True Human antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), which will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference, occurring in Rotterdam, Netherlands, on February 08, 2018. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, XBiotech most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/'symbol=XBIT

Phase-2 Study Results Corroborate HiSCR Findings with iHS4 Scoring as a Measure of Efficacy

The Phase-2 study achieved its primary endpoint, demonstrating significant treatment benefit using the Hidradenitis Suppurativa Clinical Response (HiSCR) endpoint, a validated method used in the development of the only therapy currently approved for the treatment of HS. Investigators used data from the Phase-2 study to evaluate the iHS4 scoring method to see how it correlates with the HiSCR findings. The iHS4 scoring system has recently been proposed as a new measure of HS disease severity. The data presented is a retrospective analysis using the iHS4 score for all 20 patients who were randomized to receive either placebo or MABp1 therapy in the Phase-2, double-blind study, after 12 weeks of therapy. A 30% decrease of the iHS4 score from the baseline at week 12 was associated with 100% sensitivity for positive HiSCR score. This change was found in one and in four patients allocated to placebo and MABp1, respectively.

Publication of Data from HS Phase-2 Study in the "Journal of Investigative Dermatology'

In December 2017, results of the Phase-2 study were published in the Journal of Investigative Dermatology, reporting that the study met its primary endpoint and demonstrated a significant improvement in HS patients treated with MABp1 compared to control after 12 weeks of therapy.

FDA Approved Drugs for Treatment of HS

In September 2015, the US Food and Drug Administration (FDA) approved the tumor necrosis factor inhibitor adalimumab (Humira, AbbVie) for the treatment of moderate to severe HS, making it the first and only FDA-approved therapy for HS. Adalimumab is recommended as a first-line treatment option in patients with HS who were unresponsive to, or intolerant of, oral antibiotics.

About MABp1

XBiotech's True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy, and tolerability.

About Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa, also known as acne inversa, is a long-term skin disease characterized by the occurrence of inflamed and swollen lumps. These are typically painful and break open releasing fluid or pus. The areas most commonly affected are the underarms, under the breasts, and groin. After healing, scar tissue remains, which may result in self-consciousness or depression.

About XBiotech Inc.

Founded in 2005 and headquartered in Austin, Texas, XBiotech is a fully-integrated global biosciences Company dedicated to pioneering the discovery, development, and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. The Company is advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions, and infectious diseases.

Stock Performance Snapshot

January 26, 2018 - At Friday's closing bell, XBiotech's stock dropped 5.21%, ending the trading session at $4.73.

Volume traded for the day: 254.30 thousand shares, which was above the 3-month average volume of 98.83 thousand shares.

Stock performance in the last month - up 17.37%; previous three-month period - up 16.79%; past six-month period - up 2.16%; and year-to-date - up 20.05%

After last Friday's close, XBiotech's market cap was at $161.53 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.8% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.